EyeWorld Weekly, Aril 19, 2024 – EyeWorld
➤ First patient enrolled in Phase 3 trial evaluating phentolamine ophthalmic solution ➤ FDA clears IND amendment for Phase 3 retinitis pigmentosa gene therapy study ➤ Successful pre-submission meetings held for bioengineered corneal implants ➤ Study: AI chatbots pass ophthalmology board certification questions ➤ ASCRS news and events